Jiangsu Hengrui Pharmaceuticals(600276.SH) received acceptance of the application for the marketing license of SHR4640 tablets.
Hengrui Medicine (600276.SH) announced that the company has received a "Notice of Acceptance" issued by the National Medical Products Administration...
Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that the company has received the "Acceptance Notification" issued by the National Medical Products Administration. The company's application for the market approval of SHR4640 tablets has been accepted by the national drug regulatory authority. The drug is intended for the long-term treatment of primary gout with hyperuricemia.
Related Articles
Shenzhen Hello Tech Energy(301327.SZ): Strong performance hits record high, revenue and net profit both break through.
Johnson & Johnson's financial condition is stable, and Standard and Poor's has removed the downgrade warning.
HK Bull/Bear Outstanding Qty Ratio(52:48) | April 26th
Shenzhen Hello Tech Energy(301327.SZ): Strong performance hits record high, revenue and net profit both break through.
Johnson & Johnson's financial condition is stable, and Standard and Poor's has removed the downgrade warning.
HK Bull/Bear Outstanding Qty Ratio(52:48) | April 26th
RECOMMEND
Pan Gongsheng: Will implement a moderately loose monetary policy to promote high-quality development of the Chinese economy.
25/04/2025
Canadian Prime Minister Trudeau: No rush to reach agreement with Trump, US side eventually needs to face reality.
25/04/2025
Alphabet (GOOG.US, GOOGL.US) first quarter revenue and profits exceed expectations, driven by AI and cloud computing performance growth.
25/04/2025
